This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of placenta태반의 악성신생물 (태반암)

A. Classification codes C58 — Malignant neoplasm of placenta (includes choriocarcinoma, excluding hydatidiform mole; invasive mole)
B. Synonyms Choriocarcinoma, placental site trophoblastic tumor (PSTT), epithelioid trophoblastic tumor (ETT), invasive mole, gestational trophoblastic neoplasia (GTN), gestational trophoblastic disease (GTD)
C. Adult onset Very high — occurs in women of reproductive age (mainly in their 20s–40s). The risk of hydatidiform mole is increased in older pregnant women (age 35 and over) and teenage pregnant women. Choriocarcinoma can occur at any age in women with a history of pregnancy.
Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5%

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The history of gestational trophoblastic neoplasia (GTN) is intertwined with the history of chemotherapy. In 1956, Min Chiu Li and Roy Hertz of the US National Cancer Institute (NCI) achieved complete remission by administering methotrexate (MTX) to patients with metastatic choriocarcinoma. This was the first case in human history of a solid malignant tumor being cured by chemotherapy alone, and it became the cornerstone of subsequent advances in chemotherapy. Until then, choriocarcinoma was fatal in almost all patients, but the dramatic response of the tumor to MTX opened the era of curable malignancies.

Before MTX, there was virtually no means of diagnosing or treating malignant lesions arising after hydatidiform mole. In 1958, Hertz and colleagues established that choriocarcinoma could be treated with MTX monotherapy, marking the start of an integrated approach between gynecologic oncology and medical oncology. In the 1970s, actinomycin D was found to be effective for MTX-resistant low-risk GTN, and in 1979 EMA-CO (etoposide, MTX, actinomycin D, cyclophosphamide, vincristine) combination therapy was introduced for the treatment of high-risk GTN.

In Korea, as across East Asia, the incidence of hydatidiform mole and choriocarcinoma was higher than in Western countries until the 1970s–80s, and considerable clinical experience with gestational trophoblastic disease accumulated in Korea as a result. Today, monitoring of treatment response using β-hCG and risk-adapted treatment are standardized worldwide, and the FIGO/WHO classification system is used as the basis for clinical decision-making.

2. Causes

Risk factors involved in the development of gestational trophoblastic disease (GTD) are as follows. The most important antecedent event is hydatidiform mole; the risk of progression to choriocarcinoma after a complete hydatidiform mole (complete HM) is about 1,000 times higher than after a normal pregnancy. The risk of progression to GTN after a partial hydatidiform mole (partial HM) is lower than after a complete mole but still higher than after a normal pregnancy.

Among demographic risk factors, the incidence of hydatidiform mole is high in older pregnant women (age 35 and over, especially 45 and over) and teenage pregnant women. This is presumed to be related to the frequency of abnormal fertilization. A previous molar pregnancy also increases the risk of recurrence; in women with a history of hydatidiform mole, the risk of GTD recurrence in the next pregnancy is 1–2%, higher than in the general population. Oral contraceptive use, vitamin A deficiency and blood type A have been mentioned as risk factors, but the level of evidence is low.

Geographic and ethnic factors are also important; the incidence of GTD is 2–10 times higher in East Asia, Southeast Asia and Latin America than in Western countries. This appears to result from a combination of dietary factors (especially animal fat intake, vitamin A deficiency), access to health care and genetic background. Nongestational choriocarcinoma can arise from germ cell tumors (ovary, testis), and its risk factors may differ from those of the gestational type.

3. Genetics

The genetic features of gestational trophoblastic neoplasia are unique. A complete hydatidiform mole is typically diploid of paternal origin (androgenesis): it arises either when two sperm fertilize an anucleate ovum (46,XX or 46,XY) or when a haploid sperm fertilizes an anucleate ovum and then duplicates (46,XX), and it contains no maternal DNA. In contrast, a partial hydatidiform mole has a triploid (69,XXX, 69,XXY or 69,XYY) karyotype and is accompanied by a normal fetus or fetal tissue.

Among molecular abnormalities of choriocarcinoma, p57KIP2 immunostaining is useful for differentiation (negative in complete hydatidiform mole). In high-risk GTN, MDM2 amplification, EGFR overexpression and TP53 mutations are observed. Recent studies have shown that rare familial hydatidiform mole associated with GTD development is linked to variants of the NLRP7 (19q13.4) and KHDC3L (6q13) genes. These two genes are involved in maintaining maternal genomic imprinting, and when mutated, recurrent hydatidiform moles occur.

Pharmacogenomically, polymorphisms in genes involved in MTX metabolism such as DHFR (dihydrofolate reductase), MTHFR (methylenetetrahydrofolate reductase) and ABCG2 affect MTX responsiveness and toxicity. PD-L1 expression, MSI-H status, TMB and others are being studied as predictors of response to immune checkpoint inhibitors. Special forms of GTN such as PSTT and ETT have unique genetic abnormalities and differ from choriocarcinoma in chemosensitivity.

4. General epidemiology

The incidence of GTD varies greatly by region. It is highest in East and Southeast Asia, at about 1–3 per 1,000 pregnancies, and low in Western Europe and North America, at 0.5–1 per 1,000 pregnancies. In China, 1 choriocarcinoma occurs per 2,882 pregnancies, whereas in Europe and North America about 1 per 40,000 is reported. In East Asia including Korea, the incidence is declining compared with the past, presumably owing to higher socioeconomic levels, improved access to health care and dietary changes.

Hydatidiform mole accounts for 80% of all GTD, and 15–20% of these progress to GTN. The rate of progression to GTN is 15–20% after complete hydatidiform mole and 1–5% after partial hydatidiform mole. Choriocarcinoma accounts for about 25–30% of all GTN, and nongestational choriocarcinoma is very rare. PSTT (placental site trophoblastic tumor) and ETT (epithelioid trophoblastic tumor) are extremely rare tumors accounting for only 2–3% of GTN.

Data on GTD occurrence in Korea are being accumulated through the Korea Central Cancer Registry, and with the spread of β-hCG follow-up protocols after hydatidiform mole, a system for early detection of progression to GTN has become established. GTN is of great epidemiologic significance in that it is a malignancy that can be cured in nearly 100% of cases with treatment.

5. Pathophysiology

The pathogenesis of GTD starts with abnormal fertilization. In a complete hydatidiform mole, there is no normal maternal DNA and only sperm-derived paternal DNA is present, resulting in abnormal proliferation of placental villi. The essence of complete hydatidiform mole is an abnormality of maternal genomic imprinting — that is, the absence of maternal gene expression — so that fetal development does not occur and only excessive proliferation of villous trophoblast occurs.

In the mechanism of progression to GTN, hCG (human chorionic gonadotropin) plays a key role. hCG promotes proliferation, invasion and angiogenesis of trophoblastic cells and activates the PI3K/AKT, MAPK and STAT signaling pathways through the LH/hCG receptor. In malignant choriocarcinoma, an abnormal combination of syncytiotrophoblast and cytotrophoblast forms a characteristic biphasic structure with central necrosis.

Hematogenous metastasis is very rapid because trophoblastic cells are intrinsically vasoinvasive. Even in normal pregnancy, trophoblastic cells invade maternal blood vessels to establish implantation, and malignant choriocarcinoma is a state in which this invasive property has escaped control. The lungs, vagina, liver and brain are the main sites of distant metastasis, following a descending hematogenous metastatic pattern. VEGF, MMPs (matrix metalloproteinases) and loss of E-cadherin are involved in promoting metastasis.

6. Symptoms

The most common early symptom of gestational trophoblastic disease is abnormal uterine bleeding. With hydatidiform mole, vaginal bleeding occurs in early pregnancy (8–16 weeks), and grape-like tissue may be passed. Severe nausea and vomiting (hyperemesis gravidarum) is also an early symptom, related to the thyroid-stimulating effect of extremely high β-hCG levels.

When the disease has progressed to GTN, the key feature is that β-hCG levels fail to fall or rise again even after evacuation of the mole, delivery or miscarriage. Persistent irregular vaginal bleeding after pregnancy, uterine enlargement and pelvic pain may occur. Symptoms of distant metastasis include cough, hemoptysis and dyspnea with lung metastasis; headache, seizures and neurologic deficits with brain metastasis; and abdominal pain and jaundice with liver metastasis.

Rarely, symptoms of hyperthyroidism (tachycardia, sweating, weight loss) occur because β-hCG binds to the TSH receptor and stimulates the thyroid. Vaginal metastatic lesions characteristically appear as purplish vascular lesions, and care is needed because biopsy can cause severe bleeding.

7. Signs

On physical examination, uterine enlargement, with the uterus feeling larger than expected for gestational age, is common. Theca lutein cysts may form in both ovaries and be palpable as adnexal masses; these are due to hCG hyperstimulation and resolve spontaneously after treatment. Marked elevation of serum β-hCG is the key biochemical sign; levels far higher than expected in normal pregnancy (>100,000 mIU/mL) strongly suggest hydatidiform mole.

On ultrasound, a snowstorm pattern within the uterus is the characteristic imaging finding of complete hydatidiform mole. Doppler ultrasound shows increased intrauterine blood flow. Chest X-ray or CT may reveal multiple nodules indicating lung metastasis. GTN can be diagnosed when β-hCG levels fail to fall or plateau even during treatment.

The WHO/FIGO risk scoring system distinguishes low-risk (0–6 points) from high-risk (7 points or more) groups, which has a decisive influence on the choice of treatment. Histopathologically, choriocarcinoma is characterized by mixed malignant proliferation of cytotrophoblast and syncytiotrophoblast with central necrosis and without differentiated villous structures.

8. Screening

After treatment of hydatidiform mole, serial β-hCG monitoring is the most important screening strategy for early detection of progression to GTN. After evacuation of the mole (uterine curettage), serum β-hCG is measured weekly to confirm normalization. GTN is diagnosed when hCG plateaus for 3 consecutive weeks, rises for 2 consecutive weeks, or fails to normalize for 6 months or more after treatment.

After hydatidiform mole, β-hCG monitoring is continued while contraception is maintained for at least 6 months (12 months in high-risk cases). GTN may also be suspected when β-hCG levels during pregnancy or after delivery remain higher than expected normal values. When abnormal symptoms (persistent vaginal bleeding, uterine size discrepancy) are found at routine prenatal checkups, ultrasound and β-hCG testing are performed immediately.

A population screening program for GTD in the general population is not realistically justified because of the low incidence. However, in the next pregnancy of women with a previous hydatidiform mole, intensified β-hCG follow-up and early first ultrasound are recommended.

9. Diagnosis

GTN is diagnosed clinically (meeting hCG criteria after treatment of hydatidiform mole), and unlike other malignancies, treatment can begin without histologic confirmation. According to the FIGO 2002 diagnostic criteria, GTN is diagnosed when any of the following is met: ① hCG plateau over 4 or more measurements (days 1, 7, 14, 21), ② hCG rise on 2 or more consecutive measurements over 3 weeks or more, ③ persistence of hCG for 6 months or more after treatment of hydatidiform mole, ④ histologic diagnosis of choriocarcinoma.

Imaging studies include pelvic ultrasound (assessment of uterine involvement), chest CT (lung metastasis), abdominal and pelvic CT (liver, spleen and kidney metastasis) and brain MRI (brain metastasis, high-risk patients). In PSTT and ETT, β-hCG elevation may be mild, and measurement of free β-hCG may be more useful. When tissue diagnosis is possible, hCG, p57KIP2 (negative in complete hydatidiform mole), CD146 (trophoblastic marker) and others are checked by immunohistochemistry.

To calculate the WHO/FIGO risk score, age, type of antecedent pregnancy, interval between pregnancy and start of treatment, pretreatment hCG level, largest tumor size, site and number of metastases, and history of prior chemotherapy failure are combined to classify patients as 0–6 points (low risk) or 7 points or more (high risk). This classification is the key tool for determining treatment intensity.

10. Treatment

Treatment of GTN is determined by risk classification. In low-risk GTN (WHO score 0–6), single-agent chemotherapy is the first choice. The standard is methotrexate (MTX) given with folinic acid rescue, or actinomycin D alone. The complete remission rate is 70–90%, and if the first agent fails, treatment is switched to another single-agent regimen. When disease is confined to the uterus and future pregnancy is not desired, hysterectomy may be considered.

In high-risk GTN (WHO score 7 or more), EMA-CO combination therapy (etoposide, MTX, actinomycin D, cyclophosphamide, vincristine) is the standard first-line treatment, with complete remission rates reaching 75–90%. If EMA-CO fails, salvage regimens such as EP-EMA (adding etoposide, cisplatin), TP/TE (paclitaxel, cisplatin/paclitaxel, etoposide) and BEP are used. For high-risk metastatic lesions, radiotherapy (brain metastasis) and surgery (resectable resistant lesions) are combined.

PSTT and ETT are relatively less sensitive to chemotherapy, so surgery (hysterectomy) is the main treatment, and EP-EMA or TP/TE regimens are used for metastatic lesions. Cases in which immune checkpoint inhibitors (pembrolizumab) are effective in chemotherapy-refractory GTN have been reported, and clinical trials are under way. After completion of treatment, maintenance observation is carried out after confirmation of 3 consecutive normal hCG values for low-risk disease and 3–5 normal values for high-risk disease.

11. Prognosis

GTN is a malignancy that boasts a cure rate close to 100% with appropriate treatment. This is regarded as one of the most dramatic therapeutic achievements in the history of medicine. The 5-year survival rate of low-risk GTN is >99%, and even in high-risk GTN, cure is possible in 90–95% with appropriate multiagent chemotherapy.

ClassificationComplete remission rateFinal cure rate
Low-risk GTN (FIGO I–III, score 0–6)70–90% (single-agent therapy)>99%
High-risk GTN (FIGO III–IV, score ≥7)75–90% (EMA-CO)90–95%
PSTT / ETTVariable (depends on surgery)>90% if no metastasis

Poor prognostic factors include a high-risk score, liver or brain metastasis, prior chemotherapy failure, an antecedent pregnancy event other than hydatidiform mole (normal pregnancy, miscarriage, etc.) and delayed treatment. Fertility can often be preserved after treatment, and an important feature is that pregnancy after GTN treatment is possible normally without an increase in fetal malformations or obstetric complications.

12. Prevention

The key to preventing GTN is appropriate initial treatment of hydatidiform mole followed by systematic β-hCG monitoring. When hydatidiform mole is diagnosed, uterine curettage should be performed immediately, and progression to GTN should be detected early by regular β-hCG measurement. Contraception is maintained for at least 6 months (12 months for high-risk moles) after treatment of the mole to avoid confusion with hCG elevation due to a subsequent pregnancy.

When recurrent hydatidiform mole is suspected (suspected NLRP7 or KHDC3L gene variants), genetic counseling is recommended. For people with recurrent hydatidiform mole, in vitro fertilization using dizygotic donor eggs may be effective in preventing GTD recurrence. In addition, routine prenatal ultrasound in early pregnancy and β-hCG measurement in the first trimester help detect hydatidiform mole early.

Vitamin A intake and a balanced diet have been associated with reduced GTD risk in some epidemiologic studies, but direct evidence for prevention is still insufficient. Given the high cure rate of GTD, the most important public health approaches are early medical visits for suspicious symptoms, maintaining a follow-up system after hydatidiform mole, and prompt evaluation of abnormal pregnancy-related bleeding.


13. References

  1. Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93(2):361–366.
  2. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease. Am J Obstet Gynecol. 2010;203:531–539.
  3. Ngan HYS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):86–93.
  4. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet. 2010;376:717–729.
  5. Hertz R. Roy Hertz, M.D. (1909–2002): The cure of choriocarcinoma and its impact on the development of chemotherapy for cancer. Gynecol Oncol. 2003;89(2):193–198.
  6. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112(3):654–662.
  7. Mangili G, et al. Identification of risk factors for relapse in high-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2014;135(2):380–383.
  8. Korean Society of Gynecologic Oncology. Clinical practice recommendations for gestational trophoblastic disease. 2022.
  9. FIGO Oncology Committee. Revised FIGO staging for gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2018;143(Suppl 2):79–85.
  10. Ngan HYS, et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet. 2025;70275.